A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer

European Journal of Cancer

Volumn 41, Issue 4, 2005, Pages 539-548

  Bos, A M E ^a   De Vos, F Y F L ^a   De Vries, E G E ^a   Beijnen, J H ^b   Rosing, H ^b   Mourits, M J E ^a   Van Der Zee, A G J ^a   Gietema, J A ^a   Willemse, P H B ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Chemotherapy; Hycamtin; Paclitaxel; Paraplatin; Pharmacokinetics; Taxol; Topo isomerase inhibitors

Indexed keywords

CARBOPLATIN; CIMETIDINE; CLEMASTINE; DEXAMETHASONE; PACLITAXEL; TOPOTECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PERITONEAL FLUID LEVEL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUROPATHY; OVARY CANCER; PERITONITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 14344260931     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.12.003     Document Type: Article

References (34)

1. M.J. Piccart, A. du Bois, and M.E. Gore A new standard of care for treatment of ovarian cancer Eur J Cancer 36 2000 10 12
2. A. du Bois Treatment of advanced ovarian cancer Eur J Cancer 37 Suppl 9 2001 S1 S7
3. S.B. Kaye Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 2000 19 25
4. S.B. Kaye Future directions for the management of ovarian cancer Eur J Cancer 37 Suppl 9 2001 S19 S23
5. M.A. Bookman, H. Malmstrom, and G. Bolis Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J Clin Oncol 16 1998 3345 3352
6. G.J. Creemers, G. Bolis, and M. Gore Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study J Clin Oncol 14 1996 3056 3061
7. A.P. Kudelka, D. Tresukosol, and C.L. Edwards Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma J Clin Oncol 14 1996 1552 1557
8. W. ten Bokkel Huinink, M. Gore, and J. Carmichael Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J Clin Oncol 15 1997 2183 2193
9. V.M. Herben, V.R. Panday, and D.J. Richel Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer J Clin Oncol 17 1999 747 755
10. J.D. Hainsworth, H.A. Burris, and L.H. Morrisey Phase I trial of paclitaxel, carboplatin and topotecan with or without filgrastim in the treatment of patients with advanced, refractory cancer Cancer 85 1999 1179 1185
11. L.S. Hofstra, E.G. de Vries, and N.H. Mulder Intraperitoneal chemotherapy in ovarian cancer Cancer Treat Rev 26 2000 133 143
12. M. Markman Intraperitoneal therapy of ovarian cancer Semin Oncol 25 1998 356 360
13. D.S. Alberts, P.Y. Liu, and E.V. Hannigan Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1996 1950 1955
14. D.K. Armstrong, B.N. Bundy, and R. Baergen Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, inpaclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172) Proc Am Soc Clin Oncol 21 2000 201a
15. M. Markman, B.N. Bundy, and D.S. Alberts Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group J Clin Oncol 19 2001 1001 1007
16. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
17. L.S. Hofstra, A.M. Bos, and E.G. de Vries A phase I and pharmacokinetic study of intraperitoneal topotecan Br J Cancer 85 2001 1627 1633
18. S.C. Plaxe, R.D. Christen, and J. O'Quigley Phase I and pharmacokinetic study of intraperitoneal topotecan Invest New Drugs 16 1998 147 153
19. A.H. Calvert, D.R. Newell, and L.A. Gumbrell Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1989 1748 1756
20. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
21. H. Rosing, E. Doyle, and B.E. Davies High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma J Chromatogr B Biomed Appl 668 1995 107 115
22. J.H. Proost, and D.K. Meijer MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring Comput Biol Med 22 1992 55 163
23. M. Gibaldi, and D. Perrier Pharmacokinetics 1982 Dekker Publishing New York
24. Spearman C. The proof and measurement of association between two things. By C. Spearman, 1904. Am J Psychol 1987, 100, 41-471
25. Arts HJG, Mourits MJE, Willemse PHB. Intrathoracic leakage of fluid by intraperitoneal administration [submitted]
26. H.A. Burris III, A.R. Hanauske, and R.K. Johnson Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro J Natl Cancer Inst 84 1992 1816 1820
27. J.L. Abbruzzese, T. Madden, and S.M. Sugarman Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor Clin Cancer Res 2 1996 1489 1497
28. H. Hochster, L. Liebes, and J. Speyer Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study Clin Cancer Res 3 1997 1245 1252
29. L.E. Puls, J.E. Hunter, and M.M. Crane Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma Med Oncol 19 2002 25 33
30. E.K. Rowinsky, L.B. Grochow, and C.B. Hendricks Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor J Clin Oncol 10 1992 647 656
31. M.J. Dennis, J.H. Beijnen, and L.B. Grochow An overview of the clinical pharmacology of topotecan Semin Oncol 24 1997 S5
32. W.L. Furman, S.D. Baker, and C.B. Pratt Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia J Clin Oncol 14 1996 1504 1511
33. C.F. Stewart, S.D. Baker, and R.L. Heideman Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity J Clin Oncol 12 1994 1946 1954
34. M.L. Slevin, P.I. Clark, and S.P. Joel A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer J Clin Oncol 7 1989 1333 1340